Is it feasible to treat central liver tumors +/- portal vein thrombus with SBRT while minding central hepatobiliary tract constraints?
The Stanford report (Osmundson, IJROBP 2015) on central hepatobiliary tract toxicity recommended dose constraints to the cHBT that would limit dose to sub therapeutic levels for HCC and intrahepatic cholangiocarcinma. Does this mean we shouldn't treat central tumors or a portal vein thrombus with definitive SBRT?
2 Answers
Mednet MemberInvited Expert
Radiation Oncology · Memorial Sloan-Kettering Cancer Center
Answered on
Remember that biliary strictures frequently cause death in these patients because stents don't always drain after these high doses of radiation. I have personally never caused a biliary stricture. The regimens that I am using with an SBRT technique are below the threshold for biliary stricture and r...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Radiation Oncology · University of Colorado School of Medicine
Answered on
The Stanford group has done some very nice work investigating the tolerance of central liver. Given the bile duct is not often easily seen on cross sectional imaging, these authors suggest using a fixed margin (1.5 -2 cm) around the PV (from the spleno-portal confluence to the PV bifurcation) analog...
Join for free or sign in to see the full answer